Celldex Therapeutics Stock (NASDAQ:CLDX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$23.35

52W Range

$14.40 - $47.00

50D Avg

$21.18

200D Avg

$22.79

Market Cap

$1.46B

Avg Vol (3M)

$1.02M

Beta

1.13

Div Yield

-

CLDX Company Profile


Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

186

IPO Date

May 15, 1986

Website

CLDX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Service$13.00K$278.00K$56.00K
Grant$7.01M$6.61M$2.30M

Fiscal year ends in Dec 24 | Currency in USD

CLDX Financial Summary


Dec 24Dec 23Dec 22
Revenue$7.02M$6.88M$2.36M
Operating Income$-195.08M$-154.54M$-115.23M
Net Income$-157.86M$-141.43M$-122.78M
EBITDA$-191.90M$-139.03M$-104.20M
Basic EPS$-2.45$-2.92$-2.62
Diluted EPS$-2.45$-2.92$-2.62

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 21Feb 28, 22 | 4:30 PM
Q2 20Aug 06, 20 | 4:30 PM
Q2 19Aug 08, 19 | 4:30 PM

Peer Comparison


TickerCompany
CRNXCrinetics Pharmaceuticals, Inc.
FOLDAmicus Therapeutics, Inc.
BCYCBicycle Therapeutics plc
AGENAgenus Inc.
ACADACADIA Pharmaceuticals Inc.
HALOHalozyme Therapeutics, Inc.
CYTKCytokinetics, Incorporated